What is Chemomab Therapeutics Ltd DRC (CMMB) stock price today?

Chemomab Therapeutics Ltd DRC (CMMB) currently trades at $1.47 per share. The stock has a market capitalization of $11.59M and a P/E ratio of —x.

Is CMMB stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Chemomab Therapeutics Ltd DRC has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -7.07.

Is Chemomab Therapeutics Ltd DRC financially healthy?

Chemomab Therapeutics Ltd DRC's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -7.07 places it in the distress.

CMMB

Chemomab Therapeutics Ltd DRC

NASDAQ: CMMB · HEALTHCARE · BIOTECHNOLOGY

$1.47

+0.68% today

Updated 2026-04-30

Market cap

$11.59M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.44

Dividend yield

—

52W range

$1 – $6

Volume

0.1M

Market cap

$11.59M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.44

Dividend yield

—

52W range

$1 – $6

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.3

Quality

C+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-7.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

$15.00

+920.41%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -7.07 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-11.22M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-27.65M	$-24.22M	$-13.95M	$-9.07M	$-1.88M
EPS	—	—	—	—	$-1.44
Free cash flow	$-20.36M	$-23.55M	$-15.46M	$-11.22M	$-11.22M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CMMB	$11.59M	26	4.3	3.0	5.0	5.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Chemomab Therapeutics Ltd DRC trades at $1.47. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -7.07, it sits in the distress.

Frequently asked questions

What is Chemomab Therapeutics Ltd DRC's stock price?

Chemomab Therapeutics Ltd DRC (CMMB) trades at $1.47.

Is Chemomab Therapeutics Ltd DRC overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of Chemomab Therapeutics Ltd DRC (CMMB)?

The analyst target price is $15.00, representing +920.4% upside from the current price of $1.47.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-7.07 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.chemomab.com

Quick metrics

P/S ratio—

ROE-69.50%

Beta0.58

50D MA$1.70

200D MA$2.55

Shares out0.01B

Float0.51B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CMMB vs LLY →CMMB vs JNJ →CMMB vs ABBV →Stock screener →